Invivyd’s (IVVD) Buy Rating Reiterated at D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $9.00 price target on the stock.

IVVD has been the subject of several other research reports. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. HC Wainwright reduced their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.41 on Monday. Invivyd has a 1 year low of $0.38 and a 1 year high of $5.20. The firm has a 50-day moving average of $0.53 and a 200 day moving average of $0.85. The stock has a market cap of $49.52 million, a P/E ratio of -0.21 and a beta of 0.64.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 160,400 shares of Invivyd stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the transaction, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. The trade was a 3.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Institutional Trading of Invivyd

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC raised its holdings in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the period. State Street Corp boosted its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Proficio Capital Partners LLC purchased a new stake in Invivyd during the 3rd quarter valued at approximately $27,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after buying an additional 53,499 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Invivyd during the second quarter worth $115,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.